Sponsors (2)
The bill creates a structured, transparent forum intended to accelerate and de-risk rare-disease drug development, but it raises safety and conflict-of-interest risks and could strain FDA resources while requiring modest federal funding.
People with rare diseases: could get therapies developed and approved faster by aligning trial designs, endpoints, and biomarkers across stakeholders, potentially shortening development timelines.
Drug developers, including small biotech firms: gain a structured, predictable forum for early scientific discussion with FDA and other stakeholders, reducing development uncertainty and potentially lowering research costs and program delays.
Patients and clinicians: see increased transparency about stakeholder meetings and how input influenced FDA risk–benefit decisions through public transcripts, summaries, and explanations in approvals, improving accountability and public trust.
People with rare diseases and other patients: risk approvals based on less-established evidence if stakeholder consensus favors novel or surrogate endpoints, potentially leading to safety or effectiveness problems after approval.
Patients and the public: potential conflicts of interest because industry and sponsors sit on planning and steering committees, which could bias recommendations toward sponsors' commercial interests.
FDA staff and the broader review pipeline: increased meetings, required participation, and reporting could strain FDA review divisions and divert staff time from product reviews, potentially slowing other approvals or oversight.
Based on analysis of 2 sections of legislative text.
Requires HHS/FDA to arrange with the Reagan‑Udall Foundation to hold at least four annual science-focused multistakeholder meetings and establish a permanent steering committee to advise on rare disease drug development.
Introduced March 3, 2025 by Amy Klobuchar · Last progress March 3, 2025
Creates a requirement for HHS/FDA to work with the Reagan‑Udall Foundation to run recurring, foundation-led, science-focused meetings that bring together researchers, clinicians, patient groups, industry sponsors, and others to address scientific challenges in developing drugs for rare diseases. It also establishes a permanent multistakeholder steering committee within the Foundation to recommend meeting topics and advise on implementing the meeting program, with at least four meetings held each year focused on different rare conditions or groups of conditions. The meetings are intended to clarify appropriate trial designs, endpoints, biomarkers, use of natural history data, manufacturing standards, and other scientific approaches to help align developers and the agency and facilitate development and review of therapies for rare diseases.